Bradley T. Keller
Vorstandsvorsitzender bei Accuronix Therapeutics, Inc.
Profil
Bradley T.
Keller is currently the President & Chief Executive Officer at Accuronix Therapeutics, Inc. He previously worked as Vice President-Research at Lumena Pharmaceuticals, Inc. and as Principal at Skandalaris Center (Venture Capital).
Keller received his undergraduate degree from the University of Delaware and his doctorate from the University of Kansas.
Aktive Positionen von Bradley T. Keller
| Unternehmen | Position | Beginn |
|---|---|---|
Accuronix Therapeutics, Inc.
 Accuronix Therapeutics, Inc. Medical SpecialtiesHealth Technology Accuronix Therapeutics, Inc. develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk. The firm also develops new class of drugs that work by selectively targeting the s-2 (sigma-2) receptor on cancer cells to deliver cytotoxic payloads. Its s-2 receptors are expressed on the surface of rapidly proliferating cancer cells. The company was founded by William Hawkins and Robert Mach and is headquartered in St. Louis, MO. | Vorstandsvorsitzender | 01.05.2019 |
Ehemalige bekannte Positionen von Bradley T. Keller
| Unternehmen | Position | Ende |
|---|---|---|
Skandalaris Center (Venture Capital)
 Skandalaris Center (Venture Capital) Investment ManagersFinance Skandalaris Center (Skandalaris Center) is a venture capital firm subsidiary of Olin Business School founded in 2001 by Bob Skandalaris. The firm is headquartered in St. Louis, Missouri. | Corporate Officer/Principal | 30.03.2011 |
Lumena Pharmaceuticals, Inc.
 Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Bradley T. Keller
| University of Delaware | Undergraduate Degree |
| University of Kansas | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Lumena Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Health Technology |
Skandalaris Center (Venture Capital)
Skandalaris Center (Venture Capital) Investment ManagersFinance Skandalaris Center (Skandalaris Center) is a venture capital firm subsidiary of Olin Business School founded in 2001 by Bob Skandalaris. The firm is headquartered in St. Louis, Missouri. | Finance |
Accuronix Therapeutics, Inc.
Accuronix Therapeutics, Inc. Medical SpecialtiesHealth Technology Accuronix Therapeutics, Inc. develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk. The firm also develops new class of drugs that work by selectively targeting the s-2 (sigma-2) receptor on cancer cells to deliver cytotoxic payloads. Its s-2 receptors are expressed on the surface of rapidly proliferating cancer cells. The company was founded by William Hawkins and Robert Mach and is headquartered in St. Louis, MO. | Health Technology |
